C4 Therapeutics is set to advance clinical development of cemsidomide, with Phase 1 data expected in late 2025 for multiple myeloma and non-Hodgkin’s lymphoma.
Upstream Bio successfully completed its IPO, raising $255 million through the sale of 15 million shares at $17 each, marking a strong entry into the public market.
Drug Development Updates
Stay informed with timely notifications on clinical trials and research advancements.